BACKGROUND & AIMS:Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC). METHODS: This multicenter, randomized, double-blind, placebo-controlled clinical trial compared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, PA) 4 mg orally twice daily vs placebo twice daily for 12 weeks in 105 patients with mild to moderately active UC. Disease activity was measured with the Mayo score. The primary end point was clinical response (>/=2-point reduction) at week 12. Clinical remission (Mayo score </=2), endoscopic remission, and quality of life were secondary outcomes. RESULTS: After 12 weeks of therapy, 23 patients (44%) treated with rosiglitazone and 12 patients (23%) treated with placebo achieved clinical response (P = .04). Remission was achieved in 9 patients (17%) treated with rosiglitazone and 1 patient (2%) treated with placebo (P = .01). Endoscopic remission was uncommon in either treatment arm (8% rosiglitazone vs 2% placebo; P = .34). Clinical improvement was evident as early as 4 weeks after beginning treatment (P = .049). Quality of life was improved significantly at week 8 (P = .01), but not at week 4 (P = .48) or week 12 (P = .14). Serious adverse events were rare. CONCLUSIONS:Rosiglitazone was efficacious in the treatment of mild to moderately active UC.
RCT Entities:
BACKGROUND & AIMS:Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC). METHODS: This multicenter, randomized, double-blind, placebo-controlled clinical trial compared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, PA) 4 mg orally twice daily vs placebo twice daily for 12 weeks in 105 patients with mild to moderately active UC. Disease activity was measured with the Mayo score. The primary end point was clinical response (>/=2-point reduction) at week 12. Clinical remission (Mayo score </=2), endoscopic remission, and quality of life were secondary outcomes. RESULTS: After 12 weeks of therapy, 23 patients (44%) treated with rosiglitazone and 12 patients (23%) treated with placebo achieved clinical response (P = .04). Remission was achieved in 9 patients (17%) treated with rosiglitazone and 1 patient (2%) treated with placebo (P = .01). Endoscopic remission was uncommon in either treatment arm (8% rosiglitazone vs 2% placebo; P = .34). Clinical improvement was evident as early as 4 weeks after beginning treatment (P = .049). Quality of life was improved significantly at week 8 (P = .01), but not at week 4 (P = .48) or week 12 (P = .14). Serious adverse events were rare. CONCLUSIONS:Rosiglitazone was efficacious in the treatment of mild to moderately active UC.
Authors: Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti Journal: N Engl J Med Date: 2006-12-04 Impact factor: 91.245
Authors: L Dubuquoy; C Rousseaux; X Thuru; L Peyrin-Biroulet; O Romano; P Chavatte; M Chamaillard; P Desreumaux Journal: Gut Date: 2006-09 Impact factor: 23.059
Authors: Gabriel Pascual; Amy L Fong; Sumito Ogawa; Amir Gamliel; Andrew C Li; Valentina Perissi; David W Rose; Timothy M Willson; Michael G Rosenfeld; Christopher K Glass Journal: Nature Date: 2005-08-28 Impact factor: 49.962
Authors: J D Lewis; G R Lichtenstein; R B Stein; J J Deren; T A Judge; F Fogt; E E Furth; E J Demissie; L B Hurd; C G Su; S A Keilbaugh; M A Lazar; G D Wu Journal: Am J Gastroenterol Date: 2001-12 Impact factor: 10.864
Authors: Tjeerd-Pieter van Staa; Cyrus Cooper; Listy Samuels Brusse; Hubert Leufkens; Muhammad K Javaid; Nigel K Arden Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: M Adachi; R Kurotani; K Morimura; Y Shah; M Sanford; B B Madison; D L Gumucio; H E Marin; J M Peters; H A Young; F J Gonzalez Journal: Gut Date: 2006-03-17 Impact factor: 23.059
Authors: Jennifer L Lund; Til Stürmer; Carol Q Porter; Robert S Sandler; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2011-03 Impact factor: 5.325
Authors: Md Sahab Uddin; Md Tanvir Kabir; Md Jakaria; Abdullah Al Mamun; Kamal Niaz; Md Shah Amran; George E Barreto; Ghulam Md Ashraf Journal: Neurotox Res Date: 2019-05-04 Impact factor: 3.911
Authors: Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra Journal: Gastroenterology Date: 2015-04-24 Impact factor: 22.682
Authors: Nicholas P Evans; Sarah A Misyak; Eva M Schmelz; Amir J Guri; Raquel Hontecillas; Josep Bassaganya-Riera Journal: J Nutr Date: 2010-01-20 Impact factor: 4.798